AMY RIORDAN: Open Payments
NPI 1497121552 · MAYS LANDING, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$672 in 45 payments from 13 companies in 2025. Trend: 2023 $201 · 2024 $485 · 2025 $672
Food & beverage: $672
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 12 | $195 |
| Novo Nordisk Inc | 14 | $149 |
| Amgen Inc. | 4 | $72 |
| Esperion Therapeutics, Inc. | 3 | $44 |
| Phadia US Inc. | 2 | $40 |
| PFIZER INC. | 2 | $37 |
| Lilly USA, LLC | 2 | $31 |
| SANOFI-AVENTIS U.S. LLC | 1 | $21 |
| AstraZeneca Pharmaceuticals LP | 1 | $18 |
| Sumitomo Pharma America, Inc. | 1 | $18 |
Products named: UBRELVY, VRAYLAR, Ozempic, Rybelsus, QULIPTA, NEXLETOL, Wegovy, ImmunoCAP.
Industry payments across NJ — which companies pay providers there.
